JP2005502635A5 - - Google Patents

Download PDF

Info

Publication number
JP2005502635A5
JP2005502635A5 JP2003513958A JP2003513958A JP2005502635A5 JP 2005502635 A5 JP2005502635 A5 JP 2005502635A5 JP 2003513958 A JP2003513958 A JP 2003513958A JP 2003513958 A JP2003513958 A JP 2003513958A JP 2005502635 A5 JP2005502635 A5 JP 2005502635A5
Authority
JP
Japan
Prior art keywords
compound according
och
medicament
manufacture
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003513958A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005502635A (ja
JP5038582B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/022659 external-priority patent/WO2003008399A1/en
Publication of JP2005502635A publication Critical patent/JP2005502635A/ja
Publication of JP2005502635A5 publication Critical patent/JP2005502635A5/ja
Application granted granted Critical
Publication of JP5038582B2 publication Critical patent/JP5038582B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003513958A 2001-07-16 2002-07-16 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成 Expired - Lifetime JP5038582B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16
US60/305,814 2001-07-16
PCT/US2002/022659 WO2003008399A1 (en) 2001-07-16 2002-07-16 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2005112378A Division JP4708073B2 (ja) 2001-07-16 2005-04-08 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2010020146A Division JP5227348B2 (ja) 2001-07-16 2010-02-01 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成

Publications (3)

Publication Number Publication Date
JP2005502635A JP2005502635A (ja) 2005-01-27
JP2005502635A5 true JP2005502635A5 (enExample) 2005-12-22
JP5038582B2 JP5038582B2 (ja) 2012-10-03

Family

ID=23182463

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2003513958A Expired - Lifetime JP5038582B2 (ja) 2001-07-16 2002-07-16 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2005112378A Expired - Lifetime JP4708073B2 (ja) 2001-07-16 2005-04-08 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2010020146A Expired - Lifetime JP5227348B2 (ja) 2001-07-16 2010-02-01 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2013041198A Pending JP2013136618A (ja) 2001-07-16 2013-02-13 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2015097734A Pending JP2015180656A (ja) 2001-07-16 2015-04-20 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2016218570A Expired - Lifetime JP6182254B2 (ja) 2001-07-16 2016-11-09 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2005112378A Expired - Lifetime JP4708073B2 (ja) 2001-07-16 2005-04-08 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2010020146A Expired - Lifetime JP5227348B2 (ja) 2001-07-16 2010-02-01 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2013041198A Pending JP2013136618A (ja) 2001-07-16 2013-02-13 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2015097734A Pending JP2015180656A (ja) 2001-07-16 2015-04-20 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成
JP2016218570A Expired - Lifetime JP6182254B2 (ja) 2001-07-16 2016-11-09 Ｕｄｐ−グルコース：ｎ−アシルスフィンゴシングルコシルトランスフェラーゼインヒビターの合成

Country Status (15)

Country Link
US (11) US6855830B2 (enExample)
EP (3) EP1409467B1 (enExample)
JP (6) JP5038582B2 (enExample)
AT (2) ATE555102T1 (enExample)
BE (1) BE2015C029I2 (enExample)
BR (3) BR122015016314B8 (enExample)
CA (1) CA2453978C (enExample)
CY (1) CY2015028I2 (enExample)
DK (3) DK2266968T3 (enExample)
ES (3) ES2399323T3 (enExample)
FR (1) FR15C0036I2 (enExample)
IL (3) IL159905A0 (enExample)
LU (1) LU92717I2 (enExample)
PT (3) PT1409467E (enExample)
WO (1) WO2003008399A1 (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890949B1 (en) * 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CA2434028C (en) 2001-01-10 2010-11-09 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
ATE555102T1 (de) * 2001-07-16 2012-05-15 Genzyme Corp N-acylsphingosinglucosyltransferase-inhibitor
WO2003045928A1 (en) * 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (ja) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 有機エレクトロルミネッセンス装置の製造方法
BRPI0517701A8 (pt) 2004-11-10 2018-01-23 Genzyme Corp métodos de tratamento de diabetes mellitus
US8013000B2 (en) * 2005-01-26 2011-09-06 Allergan, Inc. 3-heteroaryl-3-hydroxy-2-amino-propyl amines and related compounds having analgesic and/or immuno stimlant activity
US8716327B2 (en) * 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
EP2457919B1 (en) * 2007-01-18 2019-06-05 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
WO2008109285A1 (en) 2007-03-06 2008-09-12 Allergan, Inc. Methods for treating cognitive disorders
US8623891B2 (en) * 2007-03-06 2014-01-07 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP2594565B1 (en) 2007-05-31 2018-10-24 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CN102940627A (zh) 2007-10-05 2013-02-27 简詹姆公司 使用脑酰胺衍生物治疗多囊性肾疾病的方法
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
CA2731685A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
MX2011003517A (es) * 2008-10-03 2011-05-25 Genzyme Corp Inhibidores de la glucosilceramida sintasa tipo 2-acilaminopropanol.
EP2376123A2 (en) 2008-12-16 2011-10-19 Genzyme Corporation Oligosaccharide-protein conjugates
MX358345B (es) * 2009-11-27 2018-08-14 Genzyme Corp Star Una forma amorfa y una cristalina de hemitartrato de genz 112638 como inhibidor de glucosilceramida sintasa.
KR20130012953A (ko) 2010-04-16 2013-02-05 교세라 가부시키가이샤 무선 통신 시스템, 고전력 기지국, 저전력 기지국, 및 통신 제어 방법
KR20140037082A (ko) 2011-04-22 2014-03-26 겐자임 코포레이션 가속 가공으로 변형된 산 알파 글루코시다제
WO2013059119A1 (en) 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP2968268B1 (en) * 2013-03-15 2020-07-29 Concert Pharmaceuticals Inc. Inhibitors of the enzyme udp-glucose: n-acyl-sphingosine glucosyltransferase
CN110372636B (zh) 2013-09-20 2023-03-28 生物马林药物股份有限公司 用于治疗疾病的葡萄糖神经酰胺合成酶抑制剂
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
SI3063141T1 (sl) 2013-10-29 2018-11-30 Biomarin Pharmaceutical Inc. N-(1-hidroksi-3-(pirolidinil)propan-2-il)pirolidin-3-karboksamidni derivati kot inhibitorji glukozilceramid sintaze
WO2016126572A2 (en) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
CN104557851B (zh) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 依鲁司他的制备方法
WO2016166170A1 (en) 2015-04-14 2016-10-20 Sandoz Ag Crystalline eliglustat hydrochloride
WO2017068496A1 (en) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN105646442A (zh) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 一种依利格鲁司他的制备方法
WO2017178499A1 (en) 2016-04-11 2017-10-19 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
CN106349210A (zh) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 一种制备酒石酸艾力骨司坦的方法
CN106967042B (zh) * 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 依利格鲁司他的合成方法及其中间体化合物
CN108822072B (zh) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 一种制备伊力格鲁司他的方法
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
WO2018225085A1 (en) 2017-06-05 2018-12-13 Cipla Limited Stable solid dispersions of eliglustat hemitartrate
JP2021506789A (ja) 2017-12-15 2021-02-22 ジェンザイム・コーポレーション ゴーシェ病を処置する方法
WO2019123476A1 (en) 2017-12-20 2019-06-27 Sarudbhava Formulations Private Limited Stable amorphous eliglustat premix and process for the preparation thereof
CN111217791B (zh) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 依鲁司他中间体及其制备方法
WO2020194138A1 (en) * 2019-03-22 2020-10-01 Piramal Enterprises Limited An improved process for the preparation of eliglustat and its intermediate
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
JP7698320B2 (ja) 2019-10-23 2025-06-25 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン グルコシルセラミドシンターゼ阻害剤およびそれを使用する治療方法
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
EP4142878B1 (en) 2020-04-28 2024-06-26 The Regents of The University of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
CN116120274A (zh) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 依利格鲁司他可药用盐及其晶型
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses
WO2026006099A1 (en) 2024-06-24 2026-01-02 Genzyme Corporation Eliglustat for the treatment of gaucher disease

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (de) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh Neue aromatische verbindungen, ihre herstellung und verwendung
JPH0416856A (ja) 1990-05-10 1992-01-21 Canon Inc 正帯電性非磁性トナー
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
JP3778926B2 (ja) * 1993-08-13 2006-05-24 生化学工業株式会社 神経疾患治療剤
PT742789E (pt) 1994-02-02 2000-12-29 Liposome Co Inc Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao
DE69524592T2 (de) * 1994-06-10 2002-07-18 Seikagaku Corp., Tokio/Tokyo 2-Acylaminopropanolverbindung und ihre pharmazeutische Zusammensetzung
FR2734819B1 (fr) 1995-05-31 1997-07-04 Adir Nouveaux composes de la piperazine, de la piperidine et de la 1,2,5,6-tetrahydropyridine, leur procede de preparation et les compositions pharmaceutiques les contenant
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) * 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
NO965193L (no) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminalkoholderivat og fremgangsmåte for fremstilling derav
JP3993908B2 (ja) * 1995-12-08 2007-10-17 生化学工業株式会社 アミノアルコール誘導体及び該誘導体の製造方法
JP4140984B2 (ja) 1995-12-20 2008-08-27 生化学工業株式会社 分化誘導作用を有する薬剤
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (ja) 1997-05-23 2008-01-23 生化学工業株式会社 アミノアルコール誘導体及びそれを含有する医薬
JP4176170B2 (ja) 1997-06-06 2008-11-05 生化学工業株式会社 アミノアルコール誘導体を含む医薬及び異常増殖性疾患治療薬
ES2285852T3 (es) 1998-07-27 2007-11-16 Johns Hopkins University Compuestos de diamino-propanol para el tratamiento de la isquemia.
CA2434028C (en) 2001-01-10 2010-11-09 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) * 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
ATE555102T1 (de) 2001-07-16 2012-05-15 Genzyme Corp N-acylsphingosinglucosyltransferase-inhibitor
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US8716327B2 (en) * 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease

Similar Documents

Publication Publication Date Title
JP2005502635A5 (enExample)
EA200500715A1 (ru) Новые лекарственные средства для лечения хронического обструктивного заболевания лёгких
JP2004524316A5 (enExample)
JP2005518413A5 (enExample)
JP2011504903A5 (enExample)
JP2004525908A5 (enExample)
JP2004533444A5 (enExample)
JP2007522220A5 (enExample)
JP2010540525A5 (enExample)
JP2005536503A5 (enExample)
JP2007508361A5 (enExample)
CY1112911T1 (el) Θεραπευτικος παραγοντας ηπατικης νοσου, που περιεχει παραγωγο 2-αμινο-1,3-προπανοδιολης ως δραστικο συστατικο
NZ515282A (en) Substituted phenyl compounds with immunosuppressing activity and pharmaceutical compositions
RU99101081A (ru) Режим введения ингибиторов н+, к+-атфазы
JP2006504738A5 (enExample)
CA2595544A1 (en) Compounds having analgesic and/or immunostimulant activity
JP2002527414A5 (enExample)
JP2008512408A5 (enExample)
JP2004502684A5 (enExample)
JP2007515467A5 (enExample)
JP2008545718A5 (enExample)
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
JP2005502636A5 (enExample)
JP2014504648A5 (enExample)
JP2002510667A5 (enExample)